Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory condition of the central nervous system. The extent of disability depends on the severity of the disease and the number of relapses. Although azathioprine is currently the main treatment for patients with NMOSD in Thailand, patients o...
Main Authors: | Saharat Aungsumart, Metha Apiwattanakul |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0229028 |
Similar Items
-
Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study
by: Yujuan Jiao, et al.
Published: (2018-04-01) -
Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China
by: Qiao Huang, et al.
Published: (2018-09-01) -
Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis
by: Yang Chen, et al.
Published: (2020-11-01) -
Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil
by: Mike Lin, et al.
Published: (2020-08-01) -
Health utilities and costs for neuromyelitis optica spectrum disorder
by: Bhatt, R., et al.
Published: (2022)